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Abstract: SR9009 and SR9011 are attractive as performance-enhancing substances due to their 
REV-ERB agonist effects and thus circadian rhythm modulation activity. Although no pharmaceutical 
preparations are available yet, illicit use of SR9009 and SR9011 for doping purposes can be 
anticipated, especially since SR9009 is marketed in illicit products. Therefore, the aim was to 
identify potential diagnostic metabolites via in vitro metabolic studies to ensure effective (doping) 
control. The presence of SR9009 could be demonstrated in a black market product purchased over 
the Internet. Via human liver microsomal metabolic assays, eight metabolites were detected for 
SR9009 and fourteen metabolites for SR9011 by liquid chromatography-high resolution mass 
spectrometry (LC–HRMS). Structure elucidation was performed for all metabolites by LC–HRMS 
product ion scans in both positive and negative ionization mode. Retrospective data analysis was 
applied to 1511 doping control samples previously analyzed by a full-scan LC–HRMS screening 
method to verify the presence of SR9009, SR9011 and their metabolites. So far, the presence of 
neither the parent compound nor the metabolites could be detected in routine urine samples. 
However, to further discourage use of these potentially harmful compounds, incorporation of 
SR9009 and SR9011 into screening methods is highly recommended. 
Keywords: REV-ERB agonists; SR9009; SR9011; phase I metabolism; in vitro studies; liquid 
chromatography–high resolution mass spectrometry (LC–HRMS); doping agents 
 
1. Introduction 
Physiological processes involving metabolism and behavior, e.g., activity/rest, are generally 
organized on a cycle of approximately 24 h driven by a circadian rhythm [1–3]. The nuclear receptors 
reversed-viral erythroblastosis α and β (REV-ERB α and β) regulate the expression of core clock 
proteins and therefore help to modulate the circadian rhythm [1,2,4,5]. 
Modulation of the REV-ERB activity by synthetic agonists, e.g., SR9009 and SR9011 (Figure 1), 
alters the expression of genes involved in lipid and glucose metabolism and, therefore, plays an 
important role in maintaining the energy homeostasis [1,4,6]. Effects of SR9009 and SR9011 observed 
via in vitro and in vivo animal studies were increased basal oxygen consumption, decreased 
lipogenesis, cholesterol and bile acid synthesis in the liver, increased mitochondrial content, glucose 
and fatty acid oxidation in the skeletal muscle and decreased lipid storage in the white  
adipose tissue [1,2,4,6,7]. 
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Figure 1. Chemical structures of REV-ERBα agonists SR9009 (a) and SR9011 (b). The tentative 
fragmentation patterns are also indicated (by the arrows and the parts of the molecules were 
assigned to a letter). 
The observed increase in energy expenditure and decrease in fat mass make the REV-ERB 
agonists SR9009 and SR9011 promising drug candidates for the treatment of several metabolic 
disorders [3,4,6]. At the same time, the increase in exercise capacity observed via in vivo animal 
studies [6,8] makes these compounds also attractive for performance enhancement by athletes. Such 
use can be classified as doping. The potential interest as doping agents is clearly shown by their 
popularity in discussion forums on the Internet, where they are mentioned as the ultimate “exercise 
in a pill” compounds [8–14]. Although these REV-ERB agonists are currently still undergoing 
clinical evaluation and are therefore not approved for therapeutic use, distribution in black market 
products might be expected as observed before for designer steroids [15–17], peptides [18–23], 
several selective androgen receptor modulators (SARMs) [24–26] and peroxisome proliferator 
activated receptor δ (PPARδ) agonists e.g. GW501516 [26]. 
Even though not explicitly mentioned on the Prohibited List published by the World  
Anti-Doping Agency (WADA), they are indirectly prohibited as non-approved substances (Class S0), 
but could potentially also be classified as metabolic modulators (Class S4) [27]. 
As illicit use of SR9009 and SR9011 can be anticipated, monitoring of their presence on the 
market and use by doping control laboratories is recommended. These preventive investigations not 
only help to close the gap between anti-doping laboratories and the appearance of new doping 
agents, but also contribute to deter the use of these compounds. It would protect fair play and the 
health of athletes, as athletes are deterred from use when a substance is detectable. 
To allow a fast response to the appearance of new non-approved performance-enhancing 
substances, in vitro metabolic studies are frequently applied. As the liver is the principal organ for 
drug metabolism, in vitro models are often based on human liver fractions (e.g., human liver 
microsomes (HLM)) [28]. These in vitro studies not only circumvent the ethical objections related to 
the use of human volunteers for excretion studies, they are more affordable and can be applied 
rapidly. Moreover, analytically, the clean extracts improve the characterization of metabolites [29]. 
However, careful extrapolation of these in vitro studies to real human metabolism should be 
performed as some metabolic pathways may be over- or under-expressed [28]. Nevertheless, in vitro 
metabolic studies allow incorporating metabolites into existing screening methods, which could 
improve the detection window compared to the parent compound, and they can provide reference 
material to improve the identification of suspicious doping control samples [29]. 
In the current study, a black market product sold as a performance-enhancing product and 
labeled to contain SR9009 was purchased over the Internet to verify its content. The analysis resulted 
in the identification of the mentioned compound by liquid chromatography–(high resolution) mass 
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spectrometry (LC–(HR)MS). Consecutively, HLM were applied to perform metabolic studies of 
SR9009 and SR9011. 
2. Results 
2.1. Analysis of Black Market Product 
Reference standards of SR9009 and SR9011 were analyzed by both low resolution and high 
resolution liquid chromatography–mass spectrometry (LC–(HR)MS) instruments. The presence of 
SR9009 in the black market product was also verified by comparison with commercially available 
reference material by LC–(HR)MS. Mass deviations smaller than 1 ppm were observed for SR9009 
and SR9011 in the reference material and black market product (LC–HRMS). Identification criteria in 
chromatography and mass spectrometry, as stipulated in the WADA Technical Document [30], were 
also met for the black market product. LC–(HR)MS analysis did not result in the detection of major 
impurities (<5% total peak height in the total ion chromatogram) in the black market product. 
2.2. In Vitro Metabolic Studies 
In the current study, the metabolic fate of SR9009 and SR9011 was determined by HLM 
incubations with commercially available reference standards. The HLM incubation samples were 
analyzed by full-scan LC–HRMS analysis in both positive and negative ionization mode. The search 
for potential metabolites was complemented with the extraction of specific exact mass ions for 
“expected” metabolites, based on knowledge of HLM transformations and theoretically possible 
metabolic pathways, including oxidations (e.g., hydroxylations, double bond formation), reductions 
(e.g., ring opening), cleavage of the structure and combinations of these pathways [31,32]. 
Eight metabolites (SR09-1–SR09-8) and fourteen metabolites (SR11-1–SR11-14) were detected in 
the HLM incubation samples for SR9009 and SR9011, respectively (Figures 2 and 3). As the 
metabolites detected in all microsomal incubation samples were very similar, only the results of the 
4-h incubation sample are shown in the figures. To facilitate further discussion, the different parts of 
the molecules of both parent compounds were assigned to a letter (Figure 1 and Table 1). All 
metabolites were detected with less than a 5-ppm mass deviation from their proposed structures 
(Tables 2 and 3). 
 
Figure 2. In vitro metabolic studies with SR9009. The extracted ion liquid chromatography-high 
resolution mass spectrometry (LC–HRMS) chromatograms of the 4-h human liver microsomes 
(HLM) incubation samples (right column) are presented in comparison with blank (without HLM) 
control samples (left column). NL: normalization. 
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Table 1. Liquid chromatography-high resolution mass spectrometry (LC–HRMS) product ion scans of SR9009 and SR9011. Common product ions of the parent 
compounds and metabolites are also indicated. 
Compound Fragment 1 Chemical Formula Polarity Mode Calculated Mass (m/z) Δ ppm 2 Detected in Metabolites 
SR9009/SR9011 A C5H3NO2S + 141.9957 2.58 
SR09-: 1; 5–8 
SR11-: 1–4; 7a/b/c; 8a/b; 9–11; 14 
SR9009 B C8H11NO2 + 154.0863 0.94 SR09-: 1; 2; 6 
SR9011 B’ C11H20N2O + 197.1648 0.41 / 3 
SR9009/SR9011 C C7H5Cl + 125.0153 3.96 
SR09-: 1; 2; 3(a/b/c); 4(a/b); 5; 7; 8  
SR11-: 1–6; 9–13 
SR9009 
-C C13H17N3O4S 
+ 312.1013 1.78 SR09-1 
− 311.0945 1.30 / 3 
-C-NO2 C13H18N2O2S − 265.1016 1.25 / 3 
SR9011 
-C C16H24N4O3S + 353.1642 1.99 SR11-: 1; 7 
-C–D’ C10H13N3OS − 239.0734 1.86 SR11-: 1; 3; 9 
-C–D’-NO2 C10H14N2S − 193.0805 4.83 SR11-: 1; 9 
-D’+2H C17H20N3O2ClS + 366.1038 2.18 SR11-: 1–4; 9 
SR9009/SR9011 -E/E’ C18H18N3O3ClS + 392.0830 2.08 SR11-: 1–4 
SR9009/SR9011 C+CNH4 C8H8NCl + 154.0418 1.06 
SR09-: 3(b/c); 4b; 8 
SR11-: 1–6; 9–11; 13 
SR9009 
B-CH2 C7H11NO2 + 142.0863 0.18 SR09-: 2; 3(b/c); 4b 
-B+CH2 C13H11N2O2ClS + 295.0303 0.96 
SR09-: 1; 8  
SR11-: 10; 11 
–A C15H19N2O2Cl + 295.1208 0.72 SR09-: 1; 3a/b/c 
SR9011 B’-CH2 C10H18N2O + 183.1492 0.49 SR11-: 8b 
SR9009/SR9011 -C-E/E’ C11H13N3O3S + 268.0750 0.12 SR11-: 1, 2; 4; 7a/b; 8a; 9; 14 
1 See Figure 1 for the structures of Fragments A, B, B’, C, D, D’, E and E’; - in the fragment column: symbolizes the loss of the indicated fragment; 2 Δ ppm: mass 
deviation between calculated and experimental mass; 3 /: this fragment was not observed in metabolites. 
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Figure 3. In vitro metabolic studies with SR9011. The extracted ion LC–HRMS chromatograms of the 
4-h HLM incubation samples (right column) are presented in comparison with blank (without HLM) 
control samples (left column). NL: normalization. 
2.3. Structure Characterization by liquid chromatography-high resolution tandem mass spectrometry  
(LC–HRMS/MS) 
Initially, the fragmentation patterns of the parent compounds were studied in both positive and 
negative ionization mode to identify diagnostic product ions (Figures 1, 4 and 5). Similar fragmentation 
patterns were observed for SR9009 and SR9011 leading to diagnostic Fragments A, B/B’ and C (Table 1). 
As indicated in Figure 1, Fragment B/B’ was further fragmented for both SR9009 and SR9011, 
respectively. Structure elucidation of the SR9009 and SR9011 metabolites was based on the detection 
of structure-specific product ions by LC–HRMS (Tables 2 and 3). 
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Formula [M + H]
+ (∆ ppm) Product Ion
Polarity Mode Exp m/z 2 Chemical Formula ∆ ppm 3 Origin 1 
SR09-1 +OH C20H24N3O5ClS 454.1192 (0.94) 
+ 172.0965 C8H14NO3 1.68 B + H2O 
− 327.0895 C13H17N3O5S 0.31 -C + OH 
281.0476 C11H11N3O4S 0.09 -C-F + OH 
SR09-2 -A C15H21N2O2Cl 297.1361 (1.08) + 251.0942 C13H16N2OCl 1.42 -A-E 
SR09-3 a 
-A+OH C15H21N2O3Cl 313.1309 (1.36) + 
251.0942 C13H16N2OCl 1.38 -A-E-H2O 
225.1150 C12H18N2Cl 1.30 -A-D-H2O 
158.0811 C7H12NO3 0.63 B + CH2 + OH 
SR09-3 b 141.0100 C7H6OCl 1.12 C + OH 
SR09-3 c 267.0890 C13H16N2O2Cl 1.95 -A-F-H2O 
SR09-4 a 
-A+OH-H2 C15H19N2O3Cl 311.1148 (1.19) + 
265.0731 C13H14N2O2Cl 0.85 -F-H2O 
SR09-4 b 
293.1046 C15H18N2O2Cl 1.88 -H2O 
265.0734 C13H14N2O2Cl 1.78 -A-F-H2-H2O 
170.0364 C8H9NOCl 1.75 A + CH3NO 
SR09-5 -B C12H11N2O2SCl 283.0297 (1.88) + see 4    
SR09-6 -C+OH C13H19N3O5S 330.1112 (1.84) + 
284.0694 C11H14N3O4S 2.05 -C-F-H2O 
157.9904 C5H4NO3S 1.33 A + OH 
SR09-7 -D C17H20N3O2ClS 366.1031 (1.81) + see 4    
SR09-8 -D+OH-H2 C17H18N3O3ClS 380.0826 (1.15) + 362.07120 C17H17N3O2ClS 1.36 -H2O 
1 The structures of A, B, C, D and F’ are indicated in Figure 1 and Table 1; - in the columns of metabolic modification and origin: symbolizes the loss of the indicated 
fragment; 2 Exp m/z = experimental m/z; 3 Δ ppm: mass deviation between calculated and experimental mass; 4 see product ion scan data of the parent compounds 
presented in Table 1 for typical fragment ions of the compound(s). 
Table 3. Characterization of metabolites detected in HLM incubation samples with SR9011 by LC–HRMS analysis. 
Compound Metabolic Modification 1 Chemical Formula [M + H]
+ (∆ ppm) Product Ion
Polarity Mode Exp m/z 2 Chemical Formula ∆ ppm 3 Origin 1 
SR11-1 +OH C23H31N4O4ClS 495.1818 (1.84) 
+ 181.1333 C10H17N2O 1.49 B’-CH2-H2 
− 368.1523 C16H24N4O4S 0.34 -C+OH 
SR11-2 +2OH C23H31N4O5SCl 511.1771 (1.09) + 
242.0954 C10H16N3O2S 1.67 -C-D’-2H2O 
215.1387 C10H19N2O3 1.53 B’-CH2-H2+2OH 
SR11-3 -H2+OH C23H29N4O4ClS 493.1665 (1.24) 
+ 475.1562 C23H28N4O3ClS 0.62 -H2O 
− 366.1365 C16H22N4O4S 0.69 -C+OH-H2 
Int. J. Mol. Sci. 2016, 17, 1676 9 of 16 
 
SR11-4 -H2+2OH C23H29N4O5ClS 509.1616 (0.80) + 
409.1091 C18H22N4O3ClS 1.06 -F’-2H2O 
242.0952 C10H16N3O2S 2.33 -C-D’-2H2O 
227.1387 C11H19N2O3 1.45 B’+2OH-H2 
213.1230 C10H17N2O3 1.59 B’-CH2+2OH 
SR11-5 -A+OH C18H28N3O2Cl 354.1932 (3.11) + 
225.1147 C12H18N2Cl 2.81 -A-D’-H2O 
197.1489 C11H19N2O 1.28 B’ 
144.1130 C6H14N3O 1.24 B’-F’ 
SR11-6 -A+OH-H2 C18H26N3O2Cl 352.1781 (1.59) + 
225.1149 C12H18N2Cl 1.61 -A-D’-H2O 
211.1436 C11H19N2O2 2.29 B’+OH-H2 
197.1280 C10H17N2O2 2.20 B’-CH2 + OH-H2 
SR11-7 a/b 
-C+OH C16H26N4O4S 371.1742 (1.52) + 
242.0953 C10H16N3O2S 2.00 -C-D’-H2O 
199.1438 C10H19O2N2  1.63 B’-CH2+OH 
SR11-7 c 
258.0903 C10H16N3O3S 1.51 -C-D’+OH 
229.1782 C11H23N3O2 1.30 B’+OH 
SR11-8 a 
-C+OH-H2 C16H24N4O4S 369.1587 (1.20) + 
285.1011 C11H17N4O3S 1.47 -C-F’-H2O 
242.0953 C10H16N3O2S 1.67 -C-D’-H2O 
SR11-8 b 
282.0538 C11H12N3O4S 1.89 -C-E’+OH 
256.0745 C10H14N3O3S 2.26 -C-D’+OH 
SR11-9 -F’ C18H21N4O3ClS 409.1088 (1.97) + 
283.0853 C11H15N4O3S 2.15 -F’-C 
251.0940 C13H16N2OCl 2.90 -A-E’ 
SR11-10 -F’+OH C18H21N4O4ClS 425.1051 (1.39) + 
364.0876 C17H18N3O2ClS 1.41 -D’-H2O 
237.0786 C12H14N2OCl 1.17 -A-D’+OH 
194.0729 C6H14N2O3S 4.92 A+CH2+OH 
SR11-11 -F’-H2 C18H19N4O3ClS 407.0932 (1.83) + 
266.0588 C11H12N3O3S 2.06 -C-E’-H2 
249.0784 C13H14N2OCl 2.20 -A-E’-H2 
SR11-12 -F’-H2+OH C18H19N4O4ClS 423.1621 (1.94) + 
380.0823 C17H19N3O3ClS 1.86 -D’+OH 
282.0537 C11H12N3O4S 2.21 -C-E’+OH 
256.0746 C10H14N3O3S 2.03 -C-D’+OH 
SR11-13 -F’-A C13H18N3OCl 268.1205 (2.15) + 225.1149  C12H18N2Cl 1.66 -A-D’ 
SR11-14 -F’-C C11H16N4O3S 285.1011 (1.57) + see 4    
1 The structures of A, B, C, D and F’ are indicated in Figure 1 and Table 1; - in the columns of metabolic modification and origin: symbolizes the loss of the indicated 
fragment; 2 Exp m/z = experimental m/z; 3 Δ ppm: mass deviation between calculated and experimental mass; 4 see product ion scan data of the parent compounds 
presented in Table 1 for typical fragment ions of the compound. 
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Figure 4. LC–HRMS/MS product ion scan mass spectra of SR9009 in both positive (left column) and 
negative (right column) ionization mode at a collision energy (CE) of 15 and 25 eV, respectively. 
 
Figure 5. LC–HRMS/MS product ion scan mass spectra of SR9011 in both positive (left column) and 
negative (right column) ionization mode at a collision energy (CE) of 25 eV. 
2.3.1. SR9009 
For all hydroxylated SR9009 metabolites, product ions related to a loss of water were observed 
(Table 2). 
In the product ion scan mass spectrum of SR09-1, a base peak was observed at m/z 295.0298 in 
positive ionization mode. This ion was also found for SR9009 and could be linked to C13H12O2N2ClS 
by HRMS (Table 1). Fragments A, B and C were also observed for SR09-1 (Table 1). In negative 
ionization mode, ions m/z 327.0895 and 251.0494 indicate a hydroxylation of the parent compound 
outside C and F (Table 2). In positive ionization mode, a fragment ion m/z 172.0965 was found, 
which indicates a hydroxylation in B (Table 2). 
The structure of metabolite SR09-2 corresponds to a loss of A of the parent compound. The 
product ion data were also consistent with this structure, as only Fragments B and C were observed 
(Tables 1 and 2). For metabolites SR09-5 and SR09-7, with structures corresponding to the loss of B 
and D, respectively, only product ions related to A and C were observed (Table 1). 
Metabolites SR09-3 and SR09-4 correspond to hydroxylated derivatives of SR09-2 after loss of A 
(Table 2). For all isomeric SR09-3 and SR09-4 metabolites, Fragment C was observed. In the product 
ion scan mass spectrum of SR09-3a, m/z 158.0811 was observed, which indicates a hydroxylation in B 
(m/z 142.0863), as this fragment corresponds to C7H12NO3 with a 0.63-ppm mass deviation (Table 2). 
In contrast to what was observed in the product ion scan mass spectra of all other metabolites, 
product ion m/z 154.0418 corresponding to C8H9NCl was more abundant than product ion  
m/z 125.0153 (Fragment C) for SR09-3b. For SR09-3b, m/z 141.0100 was also observed, which 
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corresponds to C7H6OCl with 1.12 ppm mass deviation and is indicative for a hydroxylation at C of 
the parent compound. For metabolites SR09-3c and SR09-4a, no indicative ions for the position of 
hydroxylation (and further oxidation (–H2)) were found. The ion m/z 170.0364 observed for SR09-4b 
would indicate a hydroxylation and subsequent keto-formation in C of the parent compound, as this 
corresponds to C8H9NOCl with a 1.75-ppm mass deviation (Table 2). 
The ion m/z 157.9904 in the product ion scan mass spectrum of SR09-6 indicates a hydroxylation 
in A (m/z 141.9957) for this metabolite (Table 2). 
Fragments A and C were observed in the product ion scan mass spectrum of SR09-8. Similar to 
metabolite SR09-1, an abundant fragment ion m/z 295.0299 was observed. Although no indicative 
ions for the position of hydroxylation were found, this base peak (m/z 295.0299) could also indicate a 
modification (hydroxylation and keto-formation) in B (outside D) (Table 2). 
2.3.2. SR9011 
For all SR9011 metabolites, except for SR11-12, the number of losses of water was identical to 
the proposed number of hydroxylations (Table 3). 
Typical product ions of Fragments A, B’ and C were observed for SR11-1, but no indicative ions 
for the position of hydroxylation were found in positive ionization mode (Tables 1 and 3). However, 
in negative ionization mode, ion m/z 368.1522 indicates a modification outside Fragment C (Table 3). 
The presence of ion m/z 215.1387 in the product ion mass spectrum of metabolite SR11-2 could 
indicate a dihydroxylation at B’ (m/z 183.1492) (Tables 1 and 3). 
For SR11-3, no diagnostic product ions for the position of hydroxylation were found in positive 
ionization mode. However, in negative ionization mode, a product ion m/z 366.1365 was observed 
for SR11-3, which is similar to ion m/z 368.1522 found for SR11-1 (Table 3). This ion indicates a 
hydroxylation and subsequent keto-formation outside C. 
Two product ions (m/z 227.1387 and 213.1230) were found for SR11-4, which could be indicative 
for a dihydroxylation, and subsequent keto-formation of one of these hydroxyl groups, in B’. 
Besides a loss of water, no diagnostic fragment ions indicating the site of hydroxylation were 
observed for SR11-5. 
Based on the presence of fragment ions m/z 211.1436 and 197.1280, the proposed site of 
hydroxylation and subsequent keto-formation of SR11-6 is B’ (Table 3). These product ions 
correspond to modified fragment ions m/z 197.1648 and 183.1492, respectively, which were observed 
for SR9011 (Table 1). 
Three isomeric compounds were detected for SR11-7(a/b/c). For both SR11-7a and SR11-7b, a 
fragment ion m/z 199.1438 was detected, which is similar to the ion m/z 197.1280 observed for SR11-6 
and indicates also a hydroxylation in B’. For SR11-7c, fragment ions m/z 229.1782 and 258.0903 
indicate a hydroxylation in B’, outside D’. 
For SR11-8b, fragment ions m/z 282.0538 and 256.0745 were observed. This first ion corresponds 
to a modified ion m/z 268.0750, which was observed for SR9011. For SR11-12, similar fragment ions 
(m/z 282.0537 and 256.0746) and an additional fragment ion m/z 380.0523 were observed. These 
fragment ions indicate a similar site of modification (hydroxylation and subsequent keto-formation) 
for SR11-8b and SR11-12, in particular in A or B’ (outside D’). For SR11-8a, no indicative ions for the 
site of hydroxylation could be identified. 
The observed fragment ions for SR11-9, SR11-11, SR11-13 and SR11-14 were consistent with the 
proposed structure for these metabolites (Table 3). By comparing the product ion scan mass spectra 
of metabolites SR11-9 and SR11-11, two indicative ions (m/z 266.0588 and 249.4784) for the position 
of the additional modification of SR11-11 could be identified. These indicative ions correspond to 
fragment ions m/z 268.0744 and 251.0940 observed for SR11-09 (Table 1). Therefore, the proposed site 
of double bond formation for SR11-11 is in B’-E’. 
The fragment ions m/z 237.0786 and 194.0729 observed in the product ion scan mass spectrum 
of SR11-10 in positive ionization mode indicate a hydroxylation at a carbon alpha (of B’ or C) to the 
central nitrogen. 
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2.4. Assay Validation 
The LOD of SR9009 and SR9011, determined by an existing screening method applied by our 
laboratory for doping control purposes [33], was 2 and 5 ng/mL, respectively. The extraction recoveries 
were 63% for SR9009 and 56% for SR9011 using a non-optimized, regularly-applied extraction protocol 
for initial testing of doping control samples (hydrolysis (β-glucuronidase/arylsulfatase, pH 5.2) and 
liquid–liquid extraction (LLE) (tert-butyl methyl ether (TBME), pH 9.5). The matrix effects were 
determined as ion enhancement of 21% and 20% for SR9009 and SR9011, respectively. 
2.5. Retrospective Analysis 
As SR9009 was purchased via the Internet from a gross sales company, which sells to Internet 
providers of performance-enhancing drugs, it was clear that the substance may already have been 
misused by athletes in the period between its introduction on the gross sales market and the 
completion of our studies. To verify the presence of SR9009, SR9011 and their metabolites in routine 
doping control samples from that period, retrospective data analysis (data reprocessing) was 
performed for a three-month period (June 2015–September 2015). Furthermore, the presence of the 
parent compounds was monitored in our routine screening method for another three months 
(September 2015–December 2015). For the retrospective data analysis, 1511 samples previously 
analyzed by our routine full scan LC–HRMS screening method [33] were reprocessed, to verify the 
presence of the parent compounds and metabolites of SR9009 and SR9011 in these samples. Misuse 
of SR9009 and SR9011 could however not be demonstrated in our study. 
3. Discussion 
The presence of SR9009 in the black market product indicates that the use of SR9009 is no longer 
a potential threat, but a real doping threat. Shortly after the purchase of the substance from the gross 
sale Internet market, the product also appeared for purchase in individual quantities from several 
Internet suppliers of performance-enhancing substances. This indicates that the substance has now 
become readily available to athletes and that detection methods need to be developed for the 
product. Metabolism studies are essential to improve detection (windows) of doping agents. Ideally, 
human excretion studies can be performed to identify diagnostic metabolites. In case of 
non-pharmaceutical substances, e.g., SR9009 and SR9011, ethical objections and safety aspects limit 
the use of human volunteers. Consequently, in vitro metabolic assays (HLM) were applied to 
perform metabolic studies of SR9009 and SR9011. 
Eight metabolites (SR09-1–SR09-8) and fourteen metabolites (SR11-1–SR11-14) were detected in 
vitro for SR9009 and SR9011 by LC–HRMS. For the characterization of the metabolites, application of 
high resolution instruments can be advantageous, e.g., the metabolic modifications could be verified 
by determining the mass deviations of the proposed chemical formulas. To further characterize the 
proposed structures of the metabolites, LC–HRMS product ion scans were performed. Initially, the 
parent compounds were studied to determine typical, diagnostic ions. The presence of these 
diagnostic or modified diagnostic fragment ions can enable the identification of the positions of the 
metabolic modifications. This metabolite identification is time consuming, but HRMS data can also 
facilitate the correlation of observed product ions to structure specific fragments of the compounds. 
Tentative structures of these metabolites, based on LC–HRMS product ion scan data, are presented 
in Figure 6. Although modifications were observed in all fragments (A, B, B’ and C), most 
modifications occurred in the B/B’ fragment of the parent compounds. However, further research 
will be needed to unequivocally identify the chemical structures of the metabolites. 
Similar metabolites for SR9009 were described in the HLM incubation and human excretion 
urine samples by Sobolevsky et al. [34]. Metabolites SR09-1 and SR09-6 were not reported in their 
study. However, two additional metabolites were detected in their study; one metabolite 
characterized by a loss of D and hydroxylation and another by a loss of C [34]. This latter metabolite 
was also described as a major human metabolite [34]. Considering the structures of SR09-6 (-C + OH) 
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and SR09-7 (-D), these metabolic modifications observed by Sobolevsky et al. seem possible in our in 
vitro incubation samples [34]. 
Sobolevsky et al. also reported similar metabolites for SR9011, but metabolites SR11-2, SR11-3 
and SR11-12 were not reported in their study [34]. Two additional metabolites were detected in their 
study, characterized by loss of C or A [34], with the latter described as a major urinary metabolite [34]. 
Since hydroxylated metabolites (SR11-5 and SR11-7), after loss of A or C, were detected, these 
metabolic modifications observed by Sobolevsky et al. seem also possible in our in vitro incubation 
samples [34]. 
 
Figure 6. Overview of in vitro metabolic studies with SR9009 and SR9011. The proposed metabolic 
modifications are also presented; the structures of A, B, C, D and F’ are indicated in Figure 1 and Table 1. 
For the position of hydroxylations, only one possible configuration is shown. 
The highest relative abundances in the HLM incubation samples with SR9009 were observed 
for metabolites SR09-1, SR09-2, SR09-4(a), SR09-5 and SR09-7. For SR9011, metabolites SR11-1, 
SR11-3, SR11-5 and SR11-9 have the highest relative abundances in vitro. Therefore, incorporation of 
metabolites SR09-1, SR09-2, SR09-4(a), SR09-5, SR09-7, SR11-1, SR11-3, SR11-5 and SR11-9 might 
improve screening for misuse of SR9009 and SR9011. However, it should be noted that this 
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assumption is only based on the relative abundances of the metabolites detected in the HLM 
incubation samples and that extrapolation from these in vitro studies to the more complex human 
situation is difficult. 
Nevertheless, in the human excretion studies with SR9009 and SR9011 of Sobolevsky et al., 
metabolites SR09-5 and SR11-5 were indeed described as major metabolites of SR9009 and SR9011, 
respectively [34]. In addition, metabolites SR11-6 and SR11-13 were described as major human 
metabolites of SR9011 [34]. 
The lack of an intact biological system can hamper the extrapolation of in vitro results to the 
human situation. When applying in vitro techniques, other pharmacokinetic processes, including 
absorption, distribution and excretion, are not covered. Whereas human administration studies 
represent a higher complexity, other factors, e.g., phase II metabolism and extrahepatic sites of 
metabolism, can influence metabolic clearance. Furthermore, HLM consists of enriched drug 
metabolizing enzymes, which restricts competition for other enzymes and limits the application of 
HLM for quantitative estimations of specific metabolic pathways. 
However, the in vitro approach offers some advantages, such as the production of cleaner and 
more concentrated extracts, which facilitates the characterization of metabolites, and they allow a 
fast response to potential new threats. Therefore, HLM can be considered as a valuable ethically 
acceptable alternative for human metabolic studies of non-pharmaceutical-grade substances. 
To circumvent the low extraction recoveries observed when applying a regularly-used sample 
preparation procedure (enzymatic hydrolysis and LLE at pH 9.5), the combination with a  
dilute-and-shoot method is recommended. 
The presence of SR9009 and SR9011 and their metabolites was verified by retrospective data 
analysis in 1511 doping control samples. Although misuse of SR9009 and SR9011 could not be 
demonstrated in our study, it is hoped that other WADA-accredited laboratories will perform a 
similar retrospective analysis. This would further close the gap between anti-doping laboratories 
and doped athletes. 
4. Materials and Methods 
4.1. Chemicals and Reagents 
A black market gross sales product, claiming to contain SR9009, was purchased over the 
Internet (to prevent athletes from purchasing this product, further details remain confidential). The 
internal standard (IS) 17α-methyltestosterone was obtained from Organon (OSS, Noord-Brabant, 
The Netherlands). 4-Hydroxytamoxifen-d5 was purchased from Toronto Research Chemicals (TRC, 
Toronto, ON, Canada). The reference standard of methandienone was obtained from the National 
Measurement Institute (NMI, Sydney, North Ryde, Australia). Reference material of SR9009 and 
SR9011 was purchased from Calbiochem (Merck Chemicals, Nottingham, UK) and Xcess Bio (San Diego, 
CA, USA), respectively. Pooled HLM from 20–30 donors, the nicotinamide adenine dinucleotide 
phosphate (NADPH) regenerating system Solutions A and B and phosphate buffer pH 7.4 all from 
Gentest were purchased from Corning (Amsterdam, The Netherlands). β-Glucuronidase/arylsulfatase 
from Helix pomatia was from Roche Diagnostics (Mannheim, Germany). Ethanol and ammonium 
acetate (NH4OAc) were purchased from Biosolve (Valkenswaard, The Netherlands). Formic acid 
(HCOOH), ammonium formate (NH4OOCH) and methanol (MeOH) were obtained from Fisher 
Scientific (Loughborough, UK). tert-Butyl methyl ether (TBME) was purchased from Macron-Avantor 
(Deventer, The Netherlands). Sodium acetate (NaOAc), sodium hydrogen carbonate (NaHCO3), 
potassium carbonate (K2CO3), ammonium iodide (NH4I) and acetic acid (HOAc) were from Merck 
(Darmstadt, Germany). LC-grade water, LC-grade MeOH and LC-grade acetonitrile (ACN) were 
purchased from J.T. Baker (Deventer, The Netherlands). Nitrogen (N2) and oxygen-free nitrogen 
(OFN) was delivered by Air Liquide (Bornem, Belgium). 
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4.2. Instrumentation 
Liquid Chromatography-(High resolution) Mass Spectrometry (LC–(HR)MS) 
The same conditions were applied for all liquid chromatography (LC) experiments using a 
Thermo Finnigan Surveyor Autosampler Plus and an MS Pump Plus (Thermo Scientific, Bremen, 
Germany). A SunFire™ C18 column (50 mm × 2.1 mm i.d., 3.5 μm) from Waters (AH Etten-Leur, The 
Netherlands) was applied for the LC separation at a flow rate of 250 μL/min. A volume of 25 μL was 
injected using the no waste injection mode. LC-grade water (Solvent A) and LC-grade MeOH 
(Solvent B) both with 1 mM NH4OAc and 0.1% HOAc were used as the mobile phase. In the gradient 
program, the percentage of Solvent B was linearly changed as follows: 0 min, 15%; 1 min, 15%; 6.5 min, 
70%; 14 min, 75%; 16.0 min, 100%; 16.9 min, 100%; 17 min, 15% and 20 min, 15%. The total run time 
was 20 min for the LC methods. 
The low resolution experiments were performed using a TSQ Quantum Discovery MAX triple 
quadrupole mass spectrometer (Thermo Scientific). For these experiments, a full-scan method was 
applied with a scan range of m/z 100–500 in both positive and negative mode. The other MS conditions 
included interface: electrospray ionization (ESI); capillary voltage: 3.5 kV; source temperature: 350 °C; 
sheath gas (N2) pressure: 50 (arbitrary units); auxiliary gas (N2) pressure: 20 (arbitrary units); tube 
lens offset: 100 V; scan time: 0.5 s. 
An Exactive mass spectrometer (Thermo Scientific) was applied for the high resolution-tandem 
mass spectrometry (HR–MS(/MS)) experiments. The instrument operated in a full-scan (both 
positive and negative) mode with a scan range of m/z 100–2000 at a resolving power of 50,000 and a 
data acquisition rate of 2 Hz. LC–HRMS product ion scans were performed by a Q-Exactive mass 
spectrometer (Thermo Scientific) for the structural investigation of metabolites. Therefore, the 
protonated and deprotonated molecules were selected as precursor ions with an isolation window of 
1.0 m/z at a resolving power of 70,000, and collision energies of 15, 25, 35 and 45 eV were applied. For 
both LC–HRMS instruments, the other MS parameters were identical to the low resolution 
instruments, except for spray voltage: 4 kV, source temperature of 250 °C and heated ESI (HESI) 
(probe heater at 300 °C). For the assay validation, an LC–HRMS screening method, as indicated  
in [33], was applied. 
4.3. In Vitro Incubation Studies 
Prior to the in vitro metabolic studies, the black market product containing SR9009 and 
available reference material of SR9011 and SR9009 were analyzed by LC–(HR)MS for purity verification. 
The reaction mixtures for the in vitro metabolic assays (phase I) consisted of 0.1 M phosphate 
buffer (pH 7.4), a 1.3 mM NADPH regenerating system and the test compound, at a final 
concentration of 40 μg/mL, dissolved in ethanol (maximum 1% ethanol). The reaction mixtures were 
first pre-incubated for 5 min at 37 °C using the Eppendorf thermomixer comfort (Rotselaar, 
Belgium). The enzymatic reactions were then initiated by adding pooled HLM, to obtain a final 
protein concentration of 0.5 mg/mL. The final samples (250 μL) were incubated at 37 °C for 2, 4 or 18 h. 
At the appropriate time, the enzymatic reactions were terminated by adding 250 μL of ice-cold 
MeOH and transferring the tubes into an ice bath for 15 min. 
Control samples were used to verify the enzymatic reactions and the stability of the test 
compounds. These control samples included system blank samples, which did not contain the test 
compound, and substrate stability samples (blank), which consist of all of the reaction components, 
except the microsomal proteins. In a positive control sample, the reference standard of methandienone 
was incubated with HLM. 
4.4. Assay Validation 
The qualitative determination of SR9009 and SR9011 was validated in human urine regarding 
specificity, extraction recovery and the limit of detection (LOD) according to the Eurachem 
guidelines [35] and in compliance with the WADA International Standards for Laboratories (ISL) [36]. 
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Specificity was tested during the validation procedure by checking for possible interfering peaks 
in the extracted ion chromatograms (EIC) at the expected retention times for SR9009 and SR9011. 
The LOD was defined as the lowest concentration that can be detected in ten human urine 
samples with a signal to noise ratio (S/N) higher than three. Ten different blank human urine 
samples (seven male and three female; pH-range from 4.72–6.89; specific gravity between 1.006 and 
1.035) were spiked at 2, 5, 10 and 20 ng/mL for SR9009 and at 2, 5, 10, 20 and 50 ng/mL for SR9011. 
For the assay validation, 4-hydroxytamoxifen-d5 was used as the internal standard. Blank urines 
and distilled water samples spiked only with this IS were also included. Sample preparation was 
performed as described in the following section (4.5. Sample Preparation). The samples were 
analyzed according to an existing LC–HRMS screening method [33] providing the data necessary to 
determine the LOD. 
The extraction recovery of SR9009 and SR9011 during sample preparation was determined  
at 20 ng/mL and at 50 ng/mL, respectively. Recovery was calculated by comparison of the mean  
peak area of the analytes for urine samples spiked before and after sample preparation 
(hydrolysis/liquid–liquid extraction (LLE), without dilution fraction). Therefore, the results of the 
ten blank urines applied for the determination of the LOD spiked with SR9009 and SR9011 before 
sample preparation were used. Another batch of the same blank urines was spiked with SR9009 and 
SR9011 after sample preparation. Additionally, matrix effects were studied at 20 ng/mL for SR9009 
and at 50 ng/mL for SR9011. Matrix effects were measured by comparing the peak area (A) of the 
analytes spiked in 10 extracted urines and in a neat standard solution following the formula: 
M. E	(%) = (A	(urine) − A	(standard	solution))A(standard	solution) 	× 	100 
4.5. Sample Preparation 
The samples of the in vitro metabolic assays were analyzed by direct injection on LC–HRMS, 
after removal of the enzymatic proteins. Briefly, the HLM incubation samples were first centrifuged at 
4 °C (12,000× g, 5 min) followed by transferring 400 μL into new tubes. Fifty microliters of the 
internal standard (IS) 17α-methyltestosterone (2 μg/mL) were added to all samples. 
The sample preparation procedure for the assay validation and the, 1511 previously analyzed, 
routine doping control samples was described before [33]. Briefly, a 10-fold dilution fraction of the 
urine sample (with 1 mM NH4OOCH/0.01% HCOOH in H2O/ACN (95/5)) was used to reconstitute 
the dried extract of this urine sample. This extract was obtained after enzymatic hydrolysis (by  
β-glucuronidase/arylsulfatase from Helix pomatia at pH 5.2 and 56 ± 5 °C) and LLE (by TBME at pH 9.5) 
of the urine sample. 
5. Conclusions 
The presence of SR9009 was demonstrated in a black market product obtained via the Internet. 
This finding highlights the high threat for the misuse of these potentially performance-enhancing 
substances and the importance of doping control laboratories to anticipate illicit use of SR9009 and 
SR9011. HLM incubations led to the detection of eight metabolites for SR9009 and fourteen metabolites 
for SR9011 by LC–(HR)MS analysis. In this study, the in vitro assays proved to be a valuable tool for 
the detection and further characterization of SR9009 and SR9011 metabolites. 
Although misuse of SR9009 and SR9011 could not be demonstrated, incorporation of these 
substances into screening methods for doping control purposes can help to discourage the use of 
these potentially harmful compounds by both amateur and professional athletes. 
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